/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Mira Pharmaceuticals Inc share price today is $1.1778, up -2.46%. The stock opened at $1.21 against the previous close of $1.22, with an intraday high of $1.215 and low of $1.185.

style

pb-0

Mira Pharmaceuticals Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$1.1778 -0.0246(-2.46%) MIRA at 13 Mar 2026 02:17 PM Drug Manufacturers - General

Lowest Today 1.185

Highest Today 1.215

Today’s Open 1.21

Prev. Close 1.22

52 Week High 2.45

52 Week Low 0.73

Day’s Range: Low 1.185 High 1.215

52-Week Range: Low 0.73 High 2.45

Mira Pharmaceuticals Inc Institutional Holdings

Mira Pharmaceuticals Inc Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Mira Pharmaceuticals Inc Fundamentals

Market Cap 51.09 M

PB Ratio 6.7673

PE Ratio 0.0

Enterprise Value 47.56 M

Total Assets 2.92 M

Volume 110910

Mira Pharmaceuticals Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M

Annual Net worth FY23:-7544444 -7.5M, FY22:-7058190 -7.1M, FY21:-2176536 -2.2M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:11161056 11.2M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:-2081619 -2.1M, Q2/2024:-1730722 -1.7M

Quarterly Net worth Q3/2025:-22694494 -22.7M, Q2/2025:-1537712 -1.5M, Q1/2025:-1783779 -1.8M, Q3/2024:-2043867 -2.0M, Q2/2024:-1691325 -1.7M

About Mira Pharmaceuticals Inc & investment objective

Company Information MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.

Organisation Drug Manufacturers - General

Employees 0

Industry Drug Manufacturers - General

CEO Mr. Erez Aminov

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*